Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated July 04, 2025, titled Suraksha Diagnostic Limited unveils Eastern India s largest & first state-of-the-art genomics lab with a grand inauguration event.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.5 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Suraksha Diagnostic has inaugurated one of Eastern India's largest and most advanced genomics labs, backed by a ₹22 crore initial investment. The company plans to invest an additional ₹46 crore over the next 24 months to build one of Asia's most advanced genomics laboratories. The lab offers services across prenatal genetics, hereditary cancer testing, and rare disease diagnostics using technologies like NGS, Sanger Sequencing, and Microarray. This positions Suraksha in the fast-growing global genetic testing market, which is projected to grow at a 22.5% CAGR from USD 38.77 billion in 2024 to USD 186.64 billion by 2035. The company, which operates 59 diagnostic centres and 166 sample collection centres across Eastern India, completed its ₹846.25 crore IPO in December 2024.
This ₹68 crore total investment over the next two years signals significant capacity expansion and a move into high-margin precision diagnostics, potentially boosting future revenue growth. Shareholders should view this as a strategic step to capture leadership in Eastern India's genomics segment, though near-term margin pressure from capex is possible.